- Home
- TLPH vs LGVN Comparison
TLPH vs LGVN Comparison
Compare TLPH & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | LGVN |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 34.0M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLPH | LGVN |
|---|---|---|
| Price | $0.77 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 168.3K | ★ 889.7K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.48 |
| 52 Week High | $1.57 | $1.83 |
Technical Indicators
Market Signals| Indicator | TLPH | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 52.01 |
| Support Level | $0.73 | $0.69 |
| Resistance Level | $0.79 | $1.23 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 49.48 | 33.87 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.